Discounted Cash Flow (DCF) Analysis Unlevered
Rain Therapeutics Inc. (RAIN)
$7.98
+0.26 (+3.37%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||
| EBITDA | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||
| EBIT | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||
| Depreciation | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Total Cash | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||
| Account Receivables | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||
| Inventories | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||
| Accounts Payable | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 7.98 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 10.66 |
| Cost of Debt | |
| Tax Rate | -0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.529 |
| Total Debt | 0.41 |
| Total Equity | 85.04 |
| Total Capital | 85.46 |
| Debt Weighting | 0.48 |
| Equity Weighting | 99.52 |
| Wacc |
Build Up Free Cash
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| EBIAT | - | - | - | - | - | - | - | - |
| Depreciation | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - |
| Capital Expenditure | -0.14 | -0.02 | -2.63 | - | - | - | - | - |
| UFCF | - | - | - | - | - | - | - | - |
| WACC | ||||||||
| PV UFCF | - | - | - | - | - | - | - | - |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.54 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -24.37 |
| Equity Value | - |
| Shares Outstanding | 10.66 |
| Equity Value Per Share | - |